Search Result

Isoforms Recommended:	CCR4

Results for "

CCR4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cathepsin (1) CCR (19) Cytochrome P450 (1) ERK (2) Filovirus (1) HIV (1) Parasite (1) SARS-CoV (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (6) Endocrinology (4) Infection (2) Inflammation/Immunology (12) Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147385

CCR4 antagonist 3	CCR	Inflammation/Immunology
CCR4 antagonist 3 is a potent chemokine receptor 4 (CCR4) antagonist with an IC₅₀ value of 1.7 μM for [ ¹²⁵I]TARC (thymus and activation regulated chemokine). CCR4 antagonist 3 inhibits binding of radiolabeled TARC and macrophage-derived chemokine (MDC) to CCR4 receptors on the surface of CEM cells. CCR4 antagonist 3 also inhibits the in vitro migration of CEM cells mediated by TARC (IC50 = 6.4 μM) .

HY-157453

CCR4 antagonist 4	CCR	Inflammation/Immunology
CCR4 antagonist 4 (compound 22) is a selective and potent antagonist of the CC chemokine receptor-4 (CCR4), with an IC₅₀ of 0.02 μM. CCR4 antagonist 4 also blocks MDC-mediated chemotaxis (IC₅₀: 0.007 μM) and Ca ²⁺ mobilization (IC₅₀: 0.003 μM). CCR4 antagonist 4 can be used for allergic inflammation research .

HY-125836

CCR4 antagonist 2	CCR	Endocrinology Cancer
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits T_reg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC₅₀ values of Ca ²⁺flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .

HY-RS02157

CCR4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CCR4 Human Pre-designed siRNA Set A contains three designed siRNAs for CCR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CCR4 Human Pre-designed siRNA Set A CCR4 Human Pre-designed siRNA Set A

HY-RS02158

Ccr4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ccr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ccr4 Mouse Pre-designed siRNA Set A Ccr4 Mouse Pre-designed siRNA Set A

HY-RS02159

Ccr4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ccr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ccr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ccr4 Rat Pre-designed siRNA Set A Ccr4 Rat Pre-designed siRNA Set A

HY-131349

CCR4-351	CCR	Cancer
CCR4-351 is an orally active, potent and selective *CCR4* antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC₅₀s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity .

HY-131349A

CCR4-351 hydrochloride	CCR	Metabolic Disease Cancer
CCR4-351 hydrochloride is an orally active, potent and selective *CCR4* antagonist. CCR4-351 hydrochloride, featuring a novel piperidinyl-azetidine motif, has IC₅₀s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 hydrochloride has antitumor activity .

HY-148494

Tivumecirnon FLX475	CCR	Cancer
Tivumecirnon (FLX475) is an orally active *CCR4* antagonist that blocks regulatory T cells from entering the tumor microenvironment, thereby reducing their interference with effective anti-tumor immune responses. Tivumecirnon has antitumor activity .

HY-P3418

CKLF1-C27	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to *CCR4* receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .

HY-P3418A

CKLF1-C27 TFA	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to *CCR4* receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .

HY-100183

GSK2239633A	CCR	Inflammation/Immunology Endocrinology
GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [ ¹²⁵I]-TARC to human CCR4 with a pIC₅₀ of 7.96 ± 0.11.

HY-109511

AZD-1678

CCR Others

AZD-1678 is a potent CCR4 receptor antagonist, with a pIC₅₀ of 8.6 .

AZD-1678	CCR	Others
AZD-1678 is a potent CCR4 receptor antagonist, with a pIC₅₀ of 8.6 .

HY-103364A

C-021 dihydrochloride 1 Publications Verification	CCR	Inflammation/Immunology
C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [ ³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM .

HY-103364

C-021 1 Publications Verification	CCR	Inflammation/Immunology
C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC₅₀s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [ ³⁵S]GTPγS from binding to the receptor with an IC₅₀ of 18 nM .

HY-P3982

CKLF1-C19	CCR	Inflammation/Immunology
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with *CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4* .

HY-148074

Zelnecirnon RPT193	CCR	Inflammation/Immunology
Zelnecirnon (RPT193) is an orally active inhibitor of *CCR4*, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research .

HY-U00064

AZD2098 4 Publications Verification	CCR	Inflammation/Immunology Endocrinology
AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor with pIC₅₀s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research .

HY-119293

K777 1 Publications Verification	Cathepsin CCR Cytochrome P450 Parasite SARS-CoV Filovirus	Infection Cancer
K777 is a potent, orally active and irreversible cysteine protease inhibitor. K777 is also a potent *CYP3A4* inhibitor with an IC₅₀ of 60 nM and a selective *CCR4* antagonist featuring the potent chemotaxis inhibition. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypansoma cruzi, and cathepsins B and L. K777 is a broad-spectrum antiviral by targeting cathepsin-mediated cell entry. K777 inhibits SARS-CoV and EBOV pseudovirus entry with IC₅₀ values of 0.68 nM and 0.87 nM, respectively .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant *anti-CCR4* monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-103360

J-113863 3 Publications Verification	CCR	Inflammation/Immunology
J-113863 is a potent and selective *CCR1* antagonist with IC₅₀ values of 0.9 nM and 5.8 nM for human and mouse *CCR1* receptors, respectively. J-113863 is also a potent antagonist of the human *CCR3* (IC₅₀ of 0.58 nM) , but a weak antagonist of the mouse *CCR3* (IC₅₀ of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .

HY-19974

TAK-220 2 Publications Verification	CCR HIV	Infection Endocrinology
TAK-220 is a selective and orally bioavailable *CCR5* antagonist, with IC₅₀s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC₅₀s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC₉₀s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs.

Cat. No.	Product Name	Target	Research Area

HY-P3418

CKLF1-C27	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to *CCR4* receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .

HY-P3982

CKLF1-C19	CCR	Inflammation/Immunology
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with *CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4* .

HY-P3418A

CKLF1-C27 TFA	CCR ERK	Inflammation/Immunology
CKLF1-C27, a C-terminal peptide of CKLF1, binds to *CCR4* receptor and activates ERK1/2 pathway. CKLF1-C27 can abrogate the effect of CKLF1 on cells by competing for CCR4 receptor. CKLF1-C27 shows great effect on promoting proliferation on HUVECs. CKLF1-C27 has the potential for psoriasis research .

Cat. No.	Product Name	Target	Research Area

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant *anti-CCR4* monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

Recombinant Proteins Recommended:

CCR4

Species:	Human (2)
Tag:	His (2)
Source:	HEK293 (1) E. coli Cell-free (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702606

CCR4 Protein, Human (Cell-Free, His)

CCR4; CMKBR4; C-C chemokine receptor type 4; C-C CKR-4; CC-CKR-4; CCR-4; CCR4; K5-5; CD antigen CD194
Human E. coli Cell-free

HY-P700399

	CCR4 Protein-VLP, Human (HEK293, His) CCR4; CMKBR4; C-C chemokine receptor type 4; C-C CKR-4; CC-CKR-4; CCR-4; CCR4; K5-5; CD antigen CD194	Human	HEK293
	CCR4 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.